Green Cross making all-out efforts for management normalization of Innocell

Published: 2012-10-12 06:57:00

Updated: 2012-10-12 06:57:00

Green Cross Corp., the largest shareholder of Innocell, a cell therapeutics company, said in its regulatory filing Wednesday that it has decided to voluntarily restrict the selling of its equities over the next three years until August 28, 2015 as part of normalizing the management of Innocell.
...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK